Scroll To Top
Treatment

Good News if You're Living With Hep C

Good News if You're Living With Hep C

Good-news-on-hep-cx400

The once-incurable disease is finally getting some attention.

A trial of the popular hepatitis C treatment Sovaldi combined with the investigational new drug Daklinza saw nearly a 100 percent cure rate in patients who took the drugs for 12 weeks, University of Cincinnati researchers report. The cure rate was only 76 percent for eight weeks of treatment. The combo was as effective in HIV-positive patients as in those who did not have HIV.

Merck has applied for FDA approval for a once-daily, single-tablet combination med for hepatitis C, containing the drugs grazoprevir and elbasvir. Merck has studied the combo as a treatment for multiple types of the virus and for hard-to-treat patients, such as those who have both HIV and hep C.

Advocate Channel - The Pride StoreOut / Advocate Magazine - Fellow Travelers & Jamie Lee Curtis

From our Sponsors

Most Popular

Latest Stories

Trudy Ring

Editor

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.